CT52923: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 9890746 |
CHEMBL ID | 102301 |
SCHEMBL ID | 2923651 |
MeSH ID | M0434469 |
Synonym |
---|
ct52923 |
4-(6,7-dimethoxy-quinazolin-4-yl)-piperazine-1-carbothioic acid (benzo[1,3]dioxol-5-ylmethyl)-amide |
4-(6,7-dimethoxy-quinazolin-4-yl)-piperazine-1-carbothioic acid (benzo[1,3]dioxol-5-ylmethyl)-amide(kn734) |
bdbm50118826 |
kn734 |
CHEMBL102301 , |
ORRFUYVNMZSYIC-UHFFFAOYSA-N |
4-(6,7-dimethoxy-4-quinazolinyl)-n-(3,4-methylenedioxybenzyl)-1-piperazinethiocarboxamide |
SCHEMBL2923651 |
205256-55-9 |
EX-A7296 |
MS-28625 |
CS-0629188 |
HY-148514 |
AKOS040758946 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Mitogen-activated protein kinase 13 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0007 | 0.4595 | 6.3000 | AID126944 |
Serine/threonine-protein kinase D3 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 1.1701 | 10.0000 | AID164945 |
Tyrosine-protein kinase ABL1 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 0.7128 | 10.0000 | AID228815 |
Epidermal growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0000 | 0.5369 | 10.0000 | AID66597 |
Protein kinase C gamma type | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 1.0354 | 10.0000 | AID164945 |
Protein kinase C beta type | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 0.5542 | 10.0000 | AID164945 |
Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0006 | 0.5676 | 5.5450 | AID50762 |
Platelet-derived growth factor receptor beta | Homo sapiens (human) | IC50 (µMol) | 0.1025 | 0.0006 | 0.8007 | 8.5000 | AID161259; AID161262; AID161394 |
Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | IC50 (µMol) | 1.0100 | 0.0007 | 0.4708 | 10.0000 | AID108255; AID1342286 |
Fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 (µMol) | 160.0000 | 0.0002 | 0.9420 | 10.0000 | AID73304 |
Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0002 | 0.5335 | 10.0000 | AID205325 |
Platelet-derived growth factor receptor alpha | Homo sapiens (human) | IC50 (µMol) | 10.4080 | 0.0001 | 0.4912 | 10.0000 | AID1342287; AID1342288; AID161262; AID35819 |
Protein kinase C alpha type | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 0.9720 | 10.0000 | AID164945 |
cAMP-dependent protein kinase catalytic subunit alpha | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0009 | 1.3241 | 9.0000 | AID164473 |
Fibroblast growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 160.0000 | 0.0004 | 0.3276 | 8.6200 | AID73304 |
Fibroblast growth factor receptor 4 | Homo sapiens (human) | IC50 (µMol) | 160.0000 | 0.0008 | 0.6217 | 8.6200 | AID73304 |
Fibroblast growth factor receptor 3 | Homo sapiens (human) | IC50 (µMol) | 160.0000 | 0.0004 | 0.2863 | 8.6200 | AID73304 |
cAMP-dependent protein kinase catalytic subunit gamma | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0009 | 1.5482 | 9.0000 | AID164473 |
cAMP-dependent protein kinase catalytic subunit beta | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0006 | 1.4848 | 9.0000 | AID164473 |
Protein kinase C eta type | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 0.7971 | 10.0000 | AID164945 |
Mitogen-activated protein kinase 3 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0025 | 3.0926 | 9.5820 | AID71170 |
Mitogen-activated protein kinase 1 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0003 | 1.6878 | 9.2000 | AID71170 |
Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 17.3000 | 0.0000 | 0.4830 | 8.8000 | AID216646 |
Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | IC50 (µMol) | 14.9000 | 0.0001 | 0.3275 | 9.5480 | AID71188 |
Protein kinase C iota type | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 2.0378 | 10.0000 | AID164945 |
Tyrosine-protein kinase ABL2 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0005 | 0.1492 | 1.0000 | AID228815 |
Mitogen-activated protein kinase 8 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0020 | 1.0173 | 5.4200 | AID219330 |
Dual specificity mitogen-activated protein kinase kinase 6 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0010 | 0.9798 | 4.5000 | AID126763 |
Mitogen-activated protein kinase 12 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0007 | 0.4728 | 6.3000 | AID126944 |
Protein kinase C epsilon type | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 0.8029 | 10.0000 | AID164945 |
Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0002 | 0.6813 | 9.7000 | AID126613 |
Protein kinase C theta type | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 0.9897 | 10.0000 | AID164945 |
Protein kinase C zeta type | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 2.4453 | 10.0000 | AID164945 |
Protein kinase C delta type | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 0.8448 | 10.0000 | AID164945 |
Serine/threonine-protein kinase D1 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 1.2319 | 10.0000 | AID164945 |
Mitogen-activated protein kinase 11 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0007 | 0.4754 | 6.3000 | AID126944 |
Mitogen-activated protein kinase 14 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0001 | 0.7266 | 7.8000 | AID126944 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |